NEW YORK–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24VNDA&src=ctag” target=”_blank”gt;$VNDAlt;/agt; lt;a href=”https://twitter.com/hashtag/classaction?src=hash” target=”_blank”gt;#classactionlt;/agt;–The law firm of Kirby
McInerney LLP is investigating potential claims against Vanda
Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA).
This investigation concerns whether Vanda has violated federal
securities laws and/or engaged in other unlawful business practices.
On February 11, 2019, Aurelius Value published an article reporting that
a qui tam lawsuit filed by a whistleblower was recently unsealed,
containing allegations of “illegal off-label promotion of both of
Vanda’s drugs, Vanda’s participation in a fraud involving doctors
writing hundreds of ‘fake prescriptions’ and pocketing cash using
Vanda-issued copay cards, falsified documents in internal systems, and
resignations of senior executives who refused to participate in illegal
On this news, shares of Vanda fell $0.95 per share or approximately 5%,
to close at $18.00 on February 11, 2019.
If you acquired Vanda securities, have information, or would like to
learn more about these claims, please contact Thomas
W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at email@example.com,
or by filling out this
contact form, to discuss your rights or interests with respect to
these matters without any cost to you.
McInerney LLP is a New York-based plaintiffs’ law firm concentrating
in securities, antitrust, and whistleblower litigation. The firm’s
efforts on behalf of shareholders in securities litigation have resulted
in recoveries totaling billions of dollars. Additional information about
the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.